Great Valley Advisor Group Inc. Boosts Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Great Valley Advisor Group Inc. boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.3% during the second quarter, HoldingsChannel.com reports. The firm owned 2,477 shares of the medical equipment provider’s stock after acquiring an additional 189 shares during the period. Great Valley Advisor Group Inc.’s holdings in Intuitive Surgical were worth $1,102,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. James Hambro & Partners raised its stake in Intuitive Surgical by 4.3% during the second quarter. James Hambro & Partners now owns 249,789 shares of the medical equipment provider’s stock worth $111,135,000 after purchasing an additional 10,344 shares during the period. NorthCrest Asset Manangement LLC raised its stake in shares of Intuitive Surgical by 3.4% in the 2nd quarter. NorthCrest Asset Manangement LLC now owns 1,410 shares of the medical equipment provider’s stock valued at $627,000 after acquiring an additional 46 shares during the period. Ipswich Investment Management Co. Inc. raised its stake in shares of Intuitive Surgical by 4.7% in the 2nd quarter. Ipswich Investment Management Co. Inc. now owns 995 shares of the medical equipment provider’s stock valued at $443,000 after acquiring an additional 45 shares during the period. Traveka Wealth LLC raised its stake in shares of Intuitive Surgical by 5.7% in the 2nd quarter. Traveka Wealth LLC now owns 648 shares of the medical equipment provider’s stock valued at $288,000 after acquiring an additional 35 shares during the period. Finally, Gemmer Asset Management LLC purchased a new position in shares of Intuitive Surgical in the 2nd quarter valued at $222,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 0.3 %

NASDAQ ISRG traded up $1.30 during trading on Wednesday, reaching $470.53. The company’s stock had a trading volume of 466,792 shares, compared to its average volume of 1,553,799. The stock has a market capitalization of $166.90 billion, a PE ratio of 84.70, a PEG ratio of 4.97 and a beta of 1.39. The business has a 50-day moving average price of $439.66 and a 200-day moving average price of $405.79. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $473.75.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the previous year, the company earned $1.18 earnings per share. Intuitive Surgical’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the sale, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the sale, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 584 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $404.41, for a total transaction of $236,175.44. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,226,681.46. The disclosure for this sale can be found here. Insiders have sold 15,372 shares of company stock valued at $6,667,430 in the last 90 days. 0.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ISRG shares. Robert W. Baird raised their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Evercore ISI lowered their price target on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a report on Friday, July 19th. Morgan Stanley raised their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Piper Sandler raised their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Finally, Jefferies Financial Group raised their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $442.30.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.